Diabetes Care Begins—and Keeps Going—in Primary Care

by Matt Baker, Physicians Office Resource

From the first abnormal glucose result to long-term risk reduction, the physician’s most valuable tool may be a workable plan and a continuing relationship.

A patient arrives for a blood pressure follow-up, mentions getting up several times each night, and leaves with an order for diabetes testing. Another has lived with type 2 diabetes for a decade, takes medications faithfully, and still cannot explain why morning glucose readings keep climbing. A third has an A1C that looks reassuring but quietly skips lunch to afford prescriptions.

These are familiar primary care encounters. They also reveal why diabetes care cannot be reduced to a laboratory value or a medication algorithm. The disease intersects with nearly everything physicians already manage: cardiovascular risk, kidney function, weight, sleep, mental health, family responsibilities, and the cost of getting through the month.

For primary care physicians, the opportunity is substantial. Earlier recognition, thoughtful treatment, and consistent follow-through can change a patient’s trajectory. The challenge is making those elements fit into ordinary practice. Although the discussion here centers on adults with type 2 diabetes, recognizing patients who need a different diagnostic or treatment pathway remains essential.

Find the disease before symptoms force the issue

Waiting for polyuria, polydipsia, or unexplained weight loss means missing opportunities to intervene earlier. The American Diabetes Association (ADA) recommends beginning screening by age 35 for otherwise eligible adults, with earlier testing for people with overweight or obesity and additional risk factors. Family history, prior gestational diabetes, hypertension, and other indicators of insulin resistance should sharpen clinical attention.¹

Testing should answer a clinical question. A1C offers convenience because fasting is unnecessary; fasting plasma glucose is widely available; and a 75-g oral glucose tolerance test can clarify cases that other approaches miss. In nonpregnant adults, diagnostic thresholds include A1C ≥6.5%, fasting plasma glucose ≥126 mg/dL, or two-hour plasma glucose ≥200 mg/dL during an oral glucose tolerance test. Random plasma glucose ≥200 mg/dL establishes diabetes when accompanied by classic hyperglycemic symptoms or a hyperglycemic crisis. Without unequivocal hyperglycemia, confirmation requires two abnormal results.¹

Prediabetes deserves an actionable response, too. An A1C of 5.7%–6.4% should prompt a conversation about risk and referral to an evidence-based prevention program when appropriate. Telling patients to “watch their sugar” leaves too much unanswered. A defined activity goal, nutrition support, and a scheduled reassessment create a more useful starting point.²

Use office testing thoughtfully

Point-of-care A1C testing can make follow-up visits more productive by putting an actionable result into the conversation while the patient is still present. Its value depends on reliable performance and a workflow that turns the result into a decision.

Diagnosis requires additional care: ADA guidance restricts point-of-care A1C use for screening and diagnosis to FDA-approved diagnostic devices used by trained personnel in CLIA-certified laboratories performing moderate-complexity testing or higher. A device’s usefulness for monitoring does not automatically establish its suitability for diagnosis.¹

A1C also has limitations. Altered red cell turnover and some hemoglobin variants can disrupt its relationship with glycemia. When the result conflicts substantially with plasma glucose or the clinical picture, investigate rather than simply repeating the same assumption. Use plasma glucose criteria for diagnosis when A1C is unreliable.¹

Finally, do not assume every adult has type 2 diabetes. Rapid deterioration, unintentional weight loss, ketosis, or an atypical presentation should raise concern for insulin deficiency and prompt appropriate evaluation and specialist involvement. Suspected ketoacidosis requires urgent assessment; outpatient diagnostic clarification must not delay necessary treatment.¹

Make the first treatment plan understandable

A new diagnosis often produces an avalanche of information. Patients may remember the word “diabetes” and very little afterward. The first conversation should establish what the diagnosis means, what happens next, and how to reach the practice with questions.

Ask what concerns the patient most. One may fear insulin because of a relative’s experience; another may worry about losing a commercial driving job. Those concerns influence treatment acceptance as surely as a formulary does. Before adding instructions, determine what the patient already believes.

Diabetes self-management education and support (DSMES) and medical nutrition therapy belong early in the care plan. Referral is especially useful at diagnosis, when goals are not being met, when complications arise, and during transitions in care. Education should teach usable skills: taking medication, recognizing glucose patterns, treating hypoglycemia, and navigating meals, activity, and illness.³

A specific plan is easier to follow than a comprehensive lecture. Agree on one or two immediate priorities, use teach-back, and arrange follow-up before the patient leaves. The next visit can build on what worked.

Treat glucose while protecting the person

For many nonpregnant adults, an A1C goal below 7% is appropriate, provided it can be achieved without significant hypoglycemia or excessive treatment burden. Individualization matters: frailty, cognitive impairment, comorbidities, life expectancy, and the patient’s preferences may justify a different target.⁴

Medication selection should begin with the whole clinical picture. Metformin remains a useful, affordable option for many patients, subject to renal function and tolerability. But established atherosclerotic cardiovascular disease, heart failure, chronic kidney disease, and obesity can change treatment priorities. Agents with demonstrated cardiovascular or kidney benefits may be indicated regardless of whether A1C is already at goal.⁵

For appropriate patients, SGLT2 inhibitors and GLP-1 receptor agonists offer benefits beyond glucose reduction. Selection must reflect the specific agent’s evidence, indications, kidney considerations, adverse effects, and affordability. Weight management may also influence the choice of GLP-1–based therapy, including dual GIP/GLP-1 receptor agonists. The practical question is which treatment best addresses this patient’s risks and can realistically be sustained.⁵

Insulin should not become a threat reserved for “failure.” Consider it promptly when hyperglycemia is symptomatic or severe, including A1C above 10% or blood glucose ≥300 mg/dL, particularly with catabolic features. Patients need a clear explanation, administration training, glucose monitoring, and a follow-up plan.⁵

Just as important, revisit medications when circumstances change. Weight loss, declining kidney function, reduced intake, or recurrent hypoglycemia may call for deintensification. A lower A1C is not automatically a better outcome if achieving it makes daily life unsafe.⁴

Turn monitoring into clinical decisions

A1C provides a useful overview, but it cannot describe every high, low, or overnight excursion. ADA guidance recommends assessing glycemic status at least twice yearly in stable patients meeting goals and more frequently—often every three months—after treatment changes or when goals are unmet.⁴

Continuous glucose monitoring (CGM) can add context that an average cannot. The 2026 ADA recommendations support CGM for adults using insulin, those using noninsulin therapies that can cause hypoglycemia, and other patients when it helps management. Device selection should reflect individual needs and preferences.⁵

The prescription is only the beginning. Patients need help interpreting trends without reacting to every fluctuation, while practices need a reliable way to review the information. Decide what question monitoring should answer: Is fasting glucose driving the A1C? Are overnight lows being missed? Is the current regimen workable on employment days?

Hypoglycemia deserves a direct question at every relevant encounter. Ask about symptoms, episodes requiring assistance, and fear of low glucose. Provide treatment instructions and prescribe glucagon for patients taking insulin or otherwise at high risk, with education for those who may need to administer it.⁵

Keep complication prevention on the agenda

Kidney protection begins with looking for disease. Assess both estimated glomerular filtration rate and urine albumin-to-creatinine ratio at least annually in all patients with type 2 diabetes. A reassuring creatinine result does not replace urine albumin testing. Established kidney disease requires monitoring tailored to severity.⁶

Abnormal findings should trigger confirmation when appropriate and a treatment review. Blood pressure management, indicated renin-angiotensin system blockade, and therapies with proven kidney benefit can alter risk. An SGLT2 inhibitor is recommended for eligible patients with type 2 diabetes and chronic kidney disease; additional therapies may be appropriate according to albuminuria, kidney function, and potassium. Progressive or atypical disease warrants nephrology involvement.⁶

Cardiovascular prevention deserves equal attention. Review blood pressure, lipids, tobacco use, and appropriate statin therapy rather than letting the glucose discussion consume the encounter. ADA’s usual on-treatment blood pressure goal is below 130/80 mmHg when safely attainable; its 2026 guidance encourages a systolic goal below 120 mmHg for individuals with high cardiovascular or kidney risk when appropriate and safe.⁷

Eye and foot care should be routine parts of the plan. Arrange a comprehensive dilated eye examination at type 2 diabetes diagnosis, with subsequent timing based on findings and risk. Perform a comprehensive foot assessment at least annually, including skin, deformity, protective sensation, and vascular status; higher-risk patients need more frequent attention.⁸

The referral itself is not the endpoint. Confirm that the patient attended, obtain the findings, and act on them. A recommendation buried in the chart cannot protect vision or prevent an ulcer.

Give lifestyle advice a chance to work

“Eat better and exercise” is familiar advice, but it provides little help with tonight’s dinner or tomorrow’s schedule. Ask about food access, cultural preferences, physical limitations, and what the patient is willing to change.

Nutrition counseling should emphasize an individualized, sustainable eating pattern. For most adults, the activity goal is at least 150 minutes of moderate-to-vigorous aerobic activity weekly, with resistance exercise and less sedentary time as appropriate. Someone who currently does very little may need to begin with a brief, achievable walk rather than a fully developed exercise prescription.³

For patients with overweight or obesity, sustained weight loss of 5%–7% can improve glycemia and other metabolic measures; larger losses may offer additional benefits. Discuss behavioral treatment, medication, and metabolic surgery when appropriate. Obesity deserves active treatment, without making patients feel that every glucose result is a verdict on their effort.⁹

Make continuity part of the prescription

The most effective plan can unravel between appointments. A medication is denied, a sensor falls off, a patient develops nausea, or a caregiver becomes unavailable. Ask specifically about cost, side effects, diabetes distress, and practical barriers before labeling the problem nonadherence.

Primary care practices can make follow-through more dependable through previsit laboratory planning, standing workflows for overdue testing, medication reconciliation, and clearly assigned responsibility for referrals. Nurses, pharmacists, dietitians, and diabetes educators extend the physician’s ability to respond. Small operational improvements can turn good intentions into completed care.

Every patient also needs individualized sick-day guidance: how to monitor, which medication adjustments may be necessary, when ketone testing is appropriate, and when to seek urgent help. Persistent vomiting, dehydration, altered mental status, or suspected ketoacidosis should never wait for a routine appointment.⁴

Diabetes care succeeds through repeated decisions made with the patient over time. Primary care physicians are positioned to connect those decisions—to notice the missed test, uncover the unaffordable prescription, adjust the treatment, and keep the next visit focused on what matters. The goal is a longer, healthier life supported by a plan the patient can actually use.

References

1. American Diabetes Association Professional Practice Committee for Diabetes. Diagnosis and classification of diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(suppl 1). doi:10.2337/dc26-S002
2. American Diabetes Association Professional Practice Committee for Diabetes. Prevention or delay of diabetes and associated comorbidities: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(suppl 1). doi:10.2337/dc26-S003
3. American Diabetes Association Professional Practice Committee for Diabetes. Facilitating positive health behaviors and well-being to improve health outcomes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(suppl 1). doi:10.2337/dc26-S005
4. American Diabetes Association Professional Practice Committee for Diabetes. Glycemic goals, hypoglycemia, and hyperglycemic crises: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(suppl 1). doi:10.2337/dc26-S006
5. American Diabetes Association Professional Practice Committee for Diabetes. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(suppl 1). doi:10.2337/dc26-S009
6. American Diabetes Association Professional Practice Committee for Diabetes. Chronic kidney disease and risk management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(suppl 1). doi:10.2337/dc26-S011
7. American Diabetes Association Professional Practice Committee for Diabetes. Cardiovascular disease and risk management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(suppl 1). doi:10.2337/dc26-S010
8. American Diabetes Association Professional Practice Committee for Diabetes. Retinopathy, neuropathy, and foot care: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(suppl 1). doi:10.2337/dc26-S012
9. American Diabetes Association Professional Practice Committee for Diabetes. Obesity and weight management for the prevention and treatment of diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(suppl 1). doi:10.2337/dc26-S008